MedTrace Logo

Latin America Registry on WatchmanTM Outcomes in Real Life

NCT03651323 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2018-08-29

No results posted yet for this study

Summary

Left atrial appendage (LAA) occlusion with WatchmanTM has emerged as viable alternative to anticoagulation therapy in randomized controlled trials. The device has FDA approved since 2015 and the firsts Latin American cases were performed in 2012. However, there is no real world data from Latin American experience in terms of success and outcomes.

Conditions

Interventions

DEVICE

Left atrial appendage closure with Watchman device

Percutaneous left atrial appendage closure using Watchman device

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Centro Medico Docente la Trinidad

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2018-11-01
Completion
2018-12-01
FDA Device
Yes

Countries

  • Venezuela

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03651323 on ClinicalTrials.gov